Today: 19 March 2026
Subscribe
Browse Category

Biotechnology 9 January 2026 - 13 January 2026

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares jumped 11.7% to $37.81 after the company raised its 2025 sales outlook to about $1.9 billion and cut its operating expense forecast by $200 million. The company reiterated its 2026 growth target and said it does not expect flu or COVID-flu shots to be approved for the 2026 season. Investors await Feb. 13 results and early-2026 cancer vaccine data with Merck.
13 January 2026
··
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
··
Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher shares fell about 0.5% after hours Monday following news of a partnership with Nvidia on AI-driven lab automation and executive departures. COO Michel Lagarde and EVP Frederick Lowery will leave in early 2026, with Marc Casper set to become chairman and CEO. Lowery will join Henry Schein as CEO in March 2026. Thermo Fisher closed regular trading at $615.45, down 0.6%.
13 January 2026
····
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience shares rose nearly 8% Monday after preliminary fiscal Q1 revenue reached about $103.7 million, beating company forecasts. DNA Synthesis and Protein Solutions sales climbed 27% to $51.1 million, while NGS Applications revenue hit $52.6 million. CEO Emily Leproust cited strong demand in both segments. Full audited results are due Feb. 2.
12 January 2026
··
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares fell 4% to $32.92 Monday after the company raised its 2025 revenue forecast to $1.9 billion and projected operating expenses of up to $5.2 billion. CFO Jamey Mock said U.S. retail vaccination rates dropped 26% in 2025. The company expects about $8.1 billion in year-end cash, including $600 million from a new loan. Investors remain cautious as pandemic demand fades and late-stage vaccine trial results approach.
12 January 2026
···
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology shares surged 29.3% to $54.20 after the company moved up its Phase 3 PIVOT-006 trial timeline, now expecting topline results in early 2026. Trading volume reached 7 million shares. Analysts raised price targets following the update and ahead of the JPMorgan Healthcare Conference. The trial enrolls over 360 bladder cancer patients and measures recurrence-free survival.
12 January 2026
··
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience shares closed Friday up 10.6% at $45.79 after swinging between $35.13 and $50.92 on heavy volume. The company disclosed a DOJ subpoena and warned of possible legal penalties and funding risks in its Oct. 31 annual report. Its auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern. No new corporate updates have been posted since the annual filing.
11 January 2026
··
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences shares fell 6.7% to $13.84 Friday, underperforming biotech peers ahead of the J.P. Morgan Healthcare Conference. Investors are watching for CEO Paul Bolno’s Tuesday update on WVE-007, its obesity drug, after December’s interim data showed a 9.4% visceral fat reduction. The company recently raised $350 million in a public offering.
11 January 2026
··
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology shares jumped nearly 29% Friday, closing at $54.20, after the company said topline Phase 3 trial data for its bladder cancer therapy will arrive in the first half of 2026, almost a year early. Morgan Stanley raised its price target to $93, citing the accelerated timeline. The PIVOT-006 trial enrolled over 360 patients at more than 90 sites.
11 January 2026
··
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology shares surged 25.1% to $52.45 after the company advanced the expected release of late-stage bladder cancer trial results to the first half of 2026. The PIVOT-006 Phase 3 trial enrolled over 360 patients and compares cretostimogene grenadenorepvec to surveillance after tumor removal. Trading volume topped 4.1 million shares by midday. Morgan Stanley raised its price target on the stock to $89.
9 January 2026
···
1 2 3 4 5 6 … 16

Stock Market Today

  • Bluesky raises $100M Series B amid CEO transition and rapid user growth
    March 19, 2026, 4:59 PM EDT. Bluesky, a social network built on the decentralized AT Protocol, announced a $100 million Series B funding round led by Bain Capital Crypto. The round, closed in April 2025 but disclosed recently, follows previous Series A and seed rounds. The funding comes as CEO Jay Graber steps down to become chief innovation officer, aiming to bring in leadership focused on commercial growth. Bluesky's user base has surged from 13 million to over 43 million globally, with its interoperable app ecosystem expanding. Despite crypto-focused investors, Bluesky has not integrated cryptocurrencies or blockchain technology directly, though its decentralized design attracts crypto interest. The new capital will help scale the team and enhance Bluesky's app and developer ecosystem, now comprising about 20 billion public data records and over 1,000 apps built on AT Protocol.
Go toTop